Journal of rheumatology research最新文献_第2页

Identification of key genes and pathways for differential diagnosis between rheumatoid arthritis and osteoarthritis based on systems biology approaches 基于系统生物学方法鉴别类风湿关节炎和骨关节炎的关键基因和途径

Journal of rheumatology research Pub Date : 2021-03-01 DOI: 10.22631/RR.2021.69997.1112

Leila Najafzadeh, M. Mahmoudi, M. Ebadi, M. D. Shasaltaneh, Ali Masoudinejad

{"title":"Identification of key genes and pathways for differential diagnosis between rheumatoid arthritis and osteoarthritis based on systems biology approaches","authors":"Leila Najafzadeh, M. Mahmoudi, M. Ebadi, M. D. Shasaltaneh, Ali Masoudinejad","doi":"10.22631/RR.2021.69997.1112","DOIUrl":"https://doi.org/10.22631/RR.2021.69997.1112","url":null,"abstract":"Rheumatoid arthritis (RA) and osteoarthritis (OA) are two of the most prevalent forms of arthritis and may exhibit common etiology and clinical manifestations. Distinguishing between them is very important in determining effective treatment and management strategies.In the present study, the Affymetrix microarray gene expression dataset (GSE55457) was retrieved from 10 healthy controls, 13 patients with RA, and 10 OA patients and analyzed to identify hub genes so as to distinguish between RA and OA by weighted gene co-expression network (WGCNA) analysis and functional enrichment analysis. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was used to construct a protein-protein interaction (PPI) network.The most significant immune pathways associated with RA disease obtained from functional enrichment analysis were Th17, Th1, and Th2 cell differentiation and cytokine-cytokine receptor interaction pathways. The results of the present study demonstrated that two hub genes, IL2RB and HLA-DOB, may help differentiate patients with RA from those with OA at the time of diagnosis. This study introduces potential pathways and candidate biomarker genes to discriminate between RA and OA.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82724919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of efficacy of Infliximab and Etanercept on Rheumatoid Arthritis patients 英夫利昔单抗与依那西普治疗类风湿性关节炎的疗效比较

Journal of rheumatology research Pub Date : 2021-03-01 DOI: 10.22631/RR.2021.69997.1113

M. Aghdashi, Seyedmostafa Seyedmardani, Maryam Forouzin, Hushyar Azari

{"title":"Comparison of efficacy of Infliximab and Etanercept on Rheumatoid Arthritis patients","authors":"M. Aghdashi, Seyedmostafa Seyedmardani, Maryam Forouzin, Hushyar Azari","doi":"10.22631/RR.2021.69997.1113","DOIUrl":"https://doi.org/10.22631/RR.2021.69997.1113","url":null,"abstract":"Background: This study aims to to compare the efficacy of infliximab and etanercept in Rheumatoid Arthritis (RA) patients to help clinicians select the most effective treatment options. Methods and Materials: This was a retrospective cohort study conducted in Urmia, Iran, from March 21, 2017, to February 20, 2018. The data were collected by checklists from RA patients referred to the rheumatology clinic of Urmia Imam Khomeini Hospital who were receiving either infliximab or eetanercept . Inclusion criteria were: the diagnosis of RA according to revised 2016 criteria of American college of Rheumatology(ACR)/ European League Against Rheumatism, patients aged over 18, consented to participate in the study and poor response to other drugs. Both genders were included. Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), Tender Joint Count (TJC), Swollen Joint Count (SJC), and Disease Activity Score (DAS) (28 scores) were analyzed before and after the treatment. Findings: In a total of 44 eligible patients, 13 patients received infliximab and 31 received etanercept . The mean age was 53.92 ± 10.94 and 52.8±64.13 in infliximab and etanercept groups, respectively. No significant differences were reported, concerning ESR (p= 0.97) and CRP (p= 0.96), while a significant decrease in the Infliximab group compared to the etanercept group was demonstrated in terms of DAS28 scores (p=0.028), Global Health (GH) (p=0.005), SJC (p=0.008), and TJC (p=0.01).Conclusion: This study demonstrated a significant difference between the two groups in the DAS scores 28, SJC, TJC, and GH.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87193195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interferon regulatory factor 5 in Rheumatoid arthritis and systemic lupus erythematosus 干扰素调节因子5在类风湿关节炎和系统性红斑狼疮中的作用

Journal of rheumatology research Pub Date : 2021-03-01 DOI: 10.22631/rr.2021.69997.1110

Hamidreza Ebrahimiyan, Z. Bagheri-Hosseinabadi, M. Abbasifard

{"title":"Interferon regulatory factor 5 in Rheumatoid arthritis and systemic lupus erythematosus","authors":"Hamidreza Ebrahimiyan, Z. Bagheri-Hosseinabadi, M. Abbasifard","doi":"10.22631/rr.2021.69997.1110","DOIUrl":"https://doi.org/10.22631/rr.2021.69997.1110","url":null,"abstract":"The interferon regulatory factor (IRF) family consists of nine members: IRF1, IRF2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, and IRF9 [1]. In the 1980s, these proteins were described as transcriptional regulators of type I interferons (IFNs), including Ifnb and Ifna genes. The function of IRF and the production of IFNβ and IFNα form the first line of defense against viral infection. Type I IFN promotes degradation of viral DNA/RNA, inhibits viral replication and particle assembly, and enhances apoptosis in infected cells. It also enhances the differentiation of dendritic cells (DCs) and polarization of TH1 to enhance the antiviral immune response [2, 3]. The importance of these proteins is highlighted by the existence of viral-encoded IRF homologous of the host IRF, but with no function to circumvent the immune response [4-7]. The IRF protein binds to DNA by conserved N-terminal DNA binding domain, which is known as the interferon-stimulated response element (ISRE) [8]. The IRF also binds other transcription factors to enhance gene expression during the immune response. The Ifnb enhancer includes regulatory elements designated as positive regulatory domains (PRD). The transcription proteins consist of four positive regulatory domains: 1 NFkB dimer (RelA/p50), 1 AP1 complex (ATF2/c-Jun), and 2 heterodimers or homodimers of IRF, and assemble at the Ifnb promoter and promotes gene expression [9-14]. Some immune cells such as plasmacytoid dendritic cells are specialized to produce a large amount of IFNα. In this study, both IRF5 and IRF7 were expressed constitutively and played important roles in IFNα production [15]. In addition to antiviral immune response, IRF proteins could also play crucial roles in transcription regulations and the regulation of other immune responses. More importantly, IRF5 could be produced in different cell types such as macrophages, B cells, and DCs and has been associated with susceptibility to different autoimmune diseases [16]. Review Article Open Access","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72739246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variety and contribution of different rheumatic diseases at rheumatology clinic of a general hospital 综合医院风湿病门诊各种风湿病的种类和贡献

Journal of rheumatology research Pub Date : 2021-03-01 DOI: 10.22631/RR.2021.69997.1111

Nafiseh Saleknezhad, S. Fallahi

{"title":"Variety and contribution of different rheumatic diseases at rheumatology clinic of a general hospital","authors":"Nafiseh Saleknezhad, S. Fallahi","doi":"10.22631/RR.2021.69997.1111","DOIUrl":"https://doi.org/10.22631/RR.2021.69997.1111","url":null,"abstract":"This study was designed to reveal the variety and contribution of different rheumatic diseases in a non-referral rheumatology outpatient clinic. In this retrospective cross-sectional study, the data in medical records of all patients visited for the first time in the rheumatology clinic of a general hospital from the beginning of April 2016 to the end of March 2017 was gathered and evaluated for demographic characteristics, complaints, and diagnoses. A total of 2063 medical records were assessed. Among them, 2006 individuals were diagnosed with a rheumatologic disease. The mean age of patients was 48.72 ± 15.51, and females constituted 74.88% of patients. The distribution of diseases was as follows: 345 (17.20%) inflammatory, 1594 (79.46%) noninflammatory, and 67 (3.34%) both groups. The most common diagnosis was knee osteoarthritis (29.42%). Frequency distribution of other common diagnoses was in the following order: periarticular disease (15.53%), nonspecific generalized pain (8.75%), lumbar discopathy (6.24%), and rheumatoid arthritis (6.20%). The most frequent complaints were knee pain (30.96%), back pain (10.18%), and hand pain (9.35%). Among periarticular diseases, plantar fasciitis (17.27%), carpal tunnel syndrome (16.36%), and rotator cuff tendinitis (12.05%) were the most frequent disorders. More than half of the diseases included degenerative joint diseases, periarticular diseases, nonspecific musculoskeletal pain, and low back pain. The most prevalent diseases should be prioritized in the curriculum of medical education for undergraduate students. Proper policies for patient education, public health programs, and modified lifestyle may reduce morbidity among patients and costs forced upon healthcare providers and governments.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"25 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81304986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous vasculitis in Multiple myeloma and other rare manifestations: case report 多发性骨髓瘤并发皮肤血管炎及其他罕见表现1例

Journal of rheumatology research Pub Date : 2020-10-01 DOI: 10.22631/RR.2020.69997.1108

M. Emam, F. Farsad, S. Basiri

引用次数: 0

Clinical characteristics associated with hospitalization and mortality of coronavirus disease-2019 (COVID-19) infection in rheumatic patients: a cross-sectional study from Iran 风湿病患者冠状病毒病-2019 (COVID-19)感染与住院和死亡率相关的临床特征:来自伊朗的横断面研究

Journal of rheumatology research Pub Date : 2020-10-01 DOI: 10.22631/RR.2020.69997.1106

S. Assar, D. Mohamadzadeh, M. Pournazari, P. Soufivand

{"title":"Clinical characteristics associated with hospitalization and mortality of coronavirus disease-2019 (COVID-19) infection in rheumatic patients: a cross-sectional study from Iran","authors":"S. Assar, D. Mohamadzadeh, M. Pournazari, P. Soufivand","doi":"10.22631/RR.2020.69997.1106","DOIUrl":"https://doi.org/10.22631/RR.2020.69997.1106","url":null,"abstract":"This study was designed to describe COVID-19 infection in rheumatic patients and to investigate possible risk factors for hospital admission and death related to COVID-19 infection considering the type of rheumatic disease and medications used to treat it. In this observational cross-sectional study, patients under follow-up in Kermanshah rheumatology units were investigated in a 6-month period between February 18 and August 22, 2020. Confirmed COVID-19 cases were collected. The following data were obtained: age, sex, rheumatic disease diagnosis, rheumatic disease medication (glucocorticoids, csDMARDs, ts/bDMARDs). Rheumatic patients were divided into two groups of hospitalized and non-hospitalized. The data from the two groups were compared. In total, 221 patients were enrolled in this study. Of these, 38 patients (17.19%) were hospitalized, and 9 patients (4.07%) died. No significant difference was observed between hospitalized and non-hospitalized patients except for vasculitis and prior use of Janus kinase inhibitors (Tofacitinib). A greater rate of hospitalized patients had vasculitis (6 (15.79%) vs. 1 (0.55%), p < 0.0001 ). A greater rate of them were on Tofacitinib therapy (2 (1.09%) vs. 0, p value = 0.03). A greater rate of patients who died used Tofacitinib (2 (22.22%) vs. 0, p value = 0.001) and Mycophenolate Mofetil (4 (44.44%) vs. 23 (10.85%), p value = 0.014). Hospitalization and mortality rates in rheumatic patients are comparable to the general population. A higher risk for hospitalization was observed only in vasculitis patients and users of Tofacitinib, and a higher risk for mortality was seen only in users of Mycophenolate Mofetil and Tofacitinib, though this finding should be interpreted with caution due to the small size of these subgroups. In conclusion, most rheumatic patients do not seem to be at higher risk for severe COVID-19.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89805309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between vitamin D serum levels and fibromyalgia disease activity 血清维生素D水平与纤维肌痛疾病活动度的关系

Journal of rheumatology research Pub Date : 2020-10-01 DOI: 10.22631/RR.2020.69997.1105

M. Aghdashi, Seyedmostafa Seyedmardani, Hushyar Azari, S. Miraki, Ashti Morovati

{"title":"Association between vitamin D serum levels and fibromyalgia disease activity","authors":"M. Aghdashi, Seyedmostafa Seyedmardani, Hushyar Azari, S. Miraki, Ashti Morovati","doi":"10.22631/RR.2020.69997.1105","DOIUrl":"https://doi.org/10.22631/RR.2020.69997.1105","url":null,"abstract":"Fibromyalgia (FM) is a chronic musculoskeletal disorder characterized by widespread, long-term pain and multiple tender points revealed in physical examination. Previous studies about the relationship between serum vitamin D level and FM have reported paradoxical results. This cross-sectional study aimed to evaluate levels of vitamin D and its relationship with the severity of FM. Based on the American College of Rheumatology (ACS) criteria, 100 female patients with FM were enrolled in this study, and their serum vitamin D levels were screened. Vitamin D deficiency is defined as a level less than 12 ng/mL; insufficiency is defined as a level between 12–29 ng/mL, and sufficiency is a level equal to or greater than 30 ng/mL. Disease severity was evaluated by symptom severity scale (SSS) score and documented using designed questionnaires. Among the 100 female FM patients enrolled in this study, the mean patient age was 35.60 years; 47% of them had vitamin D deficiency, 36% had vitamin D insufficiency, and only 17% had normal vitamin D serum levels. Vitamin D deficiency was reported among 50% of patients with an SSS score between 9 and 12, 49% of patients with an SSS score between 5 and 8, and 14.3% of patients with an SSS score between 1 and 4. There was no significant correlation between patient age and vitamin D level (p-value=0.12). Moreover, no significant correlation was found between patient age and SSS score (p-value=0.36). The current study demonstrated that there was no statistically significant relationship between FM disease activity and vitamin Dserum level.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"99 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82351461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amyloidosis in a patient with confusing RA and PsA manifestation: a case report 混淆RA和PsA表现的淀粉样变1例报告

Journal of rheumatology research Pub Date : 2020-10-01 DOI: 10.22631/RR.2020.69997.1109

A. Ahmadzadeh, S. Basiri

引用次数: 0

Glucocorticoids could be safe in COVID-19; a case series 糖皮质激素在COVID-19中可能是安全的;案例系列

Journal of rheumatology research Pub Date : 2020-10-01 DOI: 10.22631/RR.2020.69997.1104

S. Owlia, Zohreh Akhondi-Meybodi, Golbarg Mehrpoor, M. Aghaei, Z. Mirfeizi, M. Owlia, Seyed Ruhollah Mousavinasab

{"title":"Glucocorticoids could be safe in COVID-19; a case series","authors":"S. Owlia, Zohreh Akhondi-Meybodi, Golbarg Mehrpoor, M. Aghaei, Z. Mirfeizi, M. Owlia, Seyed Ruhollah Mousavinasab","doi":"10.22631/RR.2020.69997.1104","DOIUrl":"https://doi.org/10.22631/RR.2020.69997.1104","url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus which has led to a pandemic. There is no approved treatment for coronavirus disease 2019 (COVID-19). Over time, physicians came to understand that in some severe patients, glucocorticoids could be considered as a second line treatment option. As there are a limited number of reports addressing the use of glucocorticoids (GCs) in patients with moderately severe COVID-19, this article presents the results in patients who referred to our national team and received glucocorticoids as part of their medication. This descriptive and prospective study iincludes 35 clinically-diagnosed moderate to severe COVID-19 cases in outpatient and inpatient settings. Patients received intravenous dexamethasone, oral prednisolone, and pulsed methylprednisolone. Demographic data, clinical signs and symptoms, laboratory and chest CT findings of patients were recorded. On average Men comprised 60% of this group of patients. On admission Lymphocyte counts were depleted in a majority of patients (54.3%). Shortness of breath, O2 sat, and respiratory rate improved 48 to 72 hours after administration of glucocorticoids. Almost all patients had favorable clinical courses were improved during treatment with glucocorticoids, except one who had superimposed bacterial and candida infection. CT scan findings showed bilateral peripheral patchy infiltrations with ground glass opacities as the dominant pattern of lung involvement (60%). One patient was admitted to the intensive care unit. The results of our study showed that the administration of glucocorticoids in the early stages of COVID-19 disease is not only effective, but is also safe and prevents the progression of the disease.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79104329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nutritional condition and gastrointestinal symptoms in patients with systemic sclerosis 系统性硬化症患者的营养状况与胃肠道症状

Journal of rheumatology research Pub Date : 2020-10-01 DOI: 10.22631/RR.2020.69997.1103

S. Soltani, M. Pournazari

{"title":"Nutritional condition and gastrointestinal symptoms in patients with systemic sclerosis","authors":"S. Soltani, M. Pournazari","doi":"10.22631/RR.2020.69997.1103","DOIUrl":"https://doi.org/10.22631/RR.2020.69997.1103","url":null,"abstract":"Systemic sclerosis (scleroderma/SSc) is a rare, connective autoimmune multisystem disease with wide-reaching consequences. SSc is recognized by the presence of serum autoantibodies and fibroproliferative changes in the microvasculature which, in turn, results in too much accumulation of collagen fibres in the skin and internal organs. Gastrointestinal (GI) involvement is highly prevalent among SSc patients (seen in over 90% of cases). Altered GI function and subsequent nutritional disorders are common outcomes of SSc, affecting the quality of life (QoL) and possibly carrying an associated rate of morbidity and mortality. Disease-related malnourishment is also considered to have a detrimental effect on clinical outcomes. There is little information on dietary advice for SSc patients, and as GI complaints are risk factors for bad nutritional status, perceptive assessment seems to be necessary. As the SSc pathogenesis is yet to be explored, recent investigations have aimed to evaluate the effect of diet in terms of triggering or altering the course of the disease. The present review aimed to discuss current knowledge relating to the effect of nutrition on SSc pathogenesis.","PeriodicalId":87314,"journal":{"name":"Journal of rheumatology research","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72805092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1